Last updated on November 2018

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel Carboplatin and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian Fallopian Tube or Primary Peritoneal Cancer

Brief description of study

This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.

Clinical Study Identifier: NCT03038100

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: YO39523 ...

Centre L on B rard; Centre r gional; le cancer Rh ne-Alpes
Lyon, France
  Connect »

Reference Study ID Number: YO39523 ...

Centre Hospitalier Lyon Sud
Pierre Benite, France
  Connect »